Research Perspectives - Tools for Visualisation of Portfolios
EPSRC logo

EPSRC Database


Source RCUK EPSRC Data

EP/G039933/1 - RCUK-DST India Science Bridge BioPharm 2020: Entrepreneurial Opportunities for Indian/UK Scientists in the Pharmaceutical and Biotechnology Industries

Research Perspectives grant details from EPSRC portfolio

http://www.researchperspectives.org/gow.grants/grant_EPG0399331.png

Professor K Shakesheff EP/G039933/1 - RCUK-DST India Science Bridge BioPharm 2020: Entrepreneurial Opportunities for Indian/UK Scientists in the Pharmaceutical and Biotechnology Industries

Principal Investigator - Sch of Pharmacy, University of Nottingham

Other Investigators

Professor K Pawar, Co InvestigatorProfessor K Pawar

Professor CD Rudd, Co InvestigatorProfessor CD Rudd

Scheme

Standard Research

Research Areas

Process Systems: Components and Integration Process Systems: Components and Integration

Collaborators

Indian Institute of Technology Indian Institute of Technology

Indian Institute of Management Bangalore Indian Institute of Management Bangalore

Start Date

04/2009

End Date

09/2012

Value

£743,489

Similar Grants

Automatic generation of similar EPSRC grants

Similar Topics

Topic similar to the description of this grant

Grant Description

Summary and Description of the grant

The UK Pharmaceutical Industry generates annual exports of over 14 billion and an annual output per employee of 235,278 (ABPI 2006). A strong foundation for this industry is the investment in research and development (over 26% of gross output was re-invested in 2006) and innovation and knowledge transfer between Universities and Industry. The Indian Pharmaceutical and Biotechnology sectors are undergoing a dramatic evolution due to the adoption from January 2005 of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) resulting in the recognition of product patents for pharmaceuticals. Growth rates for Indian Pharmaceutical Industries has accelerated from 9.5% to 13.6% since 2005 (Associated Chambers of Commerce India) and biotechnology growth rates exceed 37% (Biospectrum). However, several factors continue to shackle growth in India: absence of synergy between industry and academia, weak intellectual property (IP) portfolios, and insufficient knowledge transfer for commercialization being some of the key impediments. Thus, India is not realizing its potential in the Biotechnology and Pharmaceutical sectors, unlike the IT sector, for instance Our BioPharm 2020 Science Bridge will exploit synergies between scientists and industries in India and the UK to create a step-change in collaborative innovation in target identification, drug discovery, drug delivery and manufacturing. The University of Nottingham (UoN), Indian Institute of Technology Kanpur (IITK) and Indian Institute of Management Bangalore (IIMB) will build on extensive collaborations with the goals of producing (a) clinical and commercial benefits from patent protected research, (b) world class human resource with a focus on interfing with Industry, and (c) to assess the supply chain and outsourcing potential for long term business engagement and policy formulation between the two countries. BioPharm 2020 will deliver patent disclosures for inventions that are possible only due to the synergistic research expertises across the Science Bridge, a substantial cohort of students and early stage career academics with hands-on experience of innovation and long-term bonds between UK and Indian companies that exploit unique capabilities in each country.

Structured Data / Microdata


Grant Event Details:
Name: RCUK-DST India Science Bridge BioPharm 2020: Entrepreneurial Opportunities for Indian/UK Scientists in the Pharmaceutical and Biotechnology Industries - EP/G039933/1
Start Date: 2009-04-20T00:00:00+00:00
End Date: 2012-09-12T00:00:00+00:00

Organization: University of Nottingham

Description: The UK Pharmaceutical Industry generates annual exports of over 14 billion and an annual output per employee of 235,278 (ABPI 2006). A strong foundation for this industry is the investment in research and development (over 26% of gross output was re-invest ...